<DOC>
	<DOCNO>NCT02051751</DOCNO>
	<brief_summary>Dose escalation part : determine high dose BYL719 administer daily basis give combination weekly paclitaxel Dose escalation part : confirm safety tolerability BYL719 paclitaxel combination</brief_summary>
	<brief_title>A Study Evaluate Potential Benefit Addition BYL719 Paclitaxel Treatment Breast Cancer Head-and-neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion For entire trial : 1 . Adult &gt; = 18 year old 2. sign Informed Consent Form ( ICF ) 3. least one measurable nonmeasurable disease per RECIST 1.1 4. tumor tissue available analysis describe protocol 5. adequate bone marrow organ function define protocol 6. able swallow retain oral medication dose escalation part , ALL PLUS 7. histologicallyconfirmed , advance unresectable solid tumor progress standard therapy ( able tolerate ) within three month screening/baseline visit standard anticancer therapy exist . 8. Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 For dose expansion part , patient ALL first six criterion PLUS either : 9 histologically/cytologicallyconfirmed HNSCC detail protocol ECOG performance status ≤ 1 : Patient Female histologically and/or cytologically confirm diagnosis breast cancer detail protocol ECOG performance status ≤ 1 Common exclusion criterion Dose escalation Dose expansion part : 1. receive previous treatment PI3K AKT inhibitor describe protocol 2. know hypersensitivity paclitaxel product contain Cremophor 3. contraindication use standard pretreatment paclitaxel 4. primary central nervous system ( CNS ) tumor CNS tumor involvement detail protocol 5. recover grade 1 better ( except alopecia ) relate side effect prior antineoplastic therapy 6. receive radiotherapy &gt; = 4 week prior start study drug , exception palliative radiotherapy , recover side effect therapy baseline Grade ≤ 1 and/or ≥ 30 % bone marrow irradiate 7. peripheral sensory neuropathy functional impairment ( CTC grade 2 neuropathy high ) 8. undergone major surgery ≤ 4 week prior start study treatment recover side effect procedure 9. clinically significant cardiac disease impair cardiac function detail protocol 10. currently receive medication know risk prolong QT interval induce Torsades de Pointes ( TdP ) treatment either discontinue switched different medication prior start study drug treatment 11. diabetes mellitus require insulin treatment and/or clinical sign 12. impaired gastrointestinal ( GI ) function GI disease describe protocol 13. know positive serology human immunodeficiency virus ( HIV ) , active Hepatitis B , and/or active Hepatitis C infection 14. condition would , Investigator 's judgment , preclude patient 's participation clinical study due safety concern compliance clinical study procedure 15. currently receive treatment drug know moderate strong inhibitor inducer isoenzymes CYP3A CYP2C8 detail protocol 16. currently receive treatment agent metabolize solely CYP3A and/or narrow therapeutic window 17. history another malignancy within 2 year prior start study treatment , except cure basal cell carcinoma skin excise carcinoma situ cervix 18 . Patient history noncompliance medical regimen inability grant consent 19 . Pregnant nursing ( lactate ) woman 20. apply highly effective contraception study duration define protocol For HNSCC patient 's cohort additional exclusion criterion : 21 Treatment one prior chemotherapy recurrent/metastatic disease detail protocol 22 Prior taxane treatment metastatic disease additional exclusion criterion breast cancer patient ' cohort : receive prior cytotoxic therapy inoperable locally advanced ( recurrent progressive ) metastatic disease , progression/recurrent disease within 6 month completion adjuvant/neoadjuvant therapy describe protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Solid tumor , Head neck non squamous cell carcinoma , breast cancer , PI3K inhibitor , BYL719 , paclitaxel</keyword>
</DOC>